Arrow Therapeutics selects a further Hepatitis C compound A-689

17-Jan-2007

Arrow Therapeutics has announced that a further hepatitis C compound, A-689, has entered full preclinical development. A-689 is the second compound from Arrow's broad approach to the NS5a target to enter development. November 2006 saw Arrow's first Hepatitis C compound, A-831, enter Phase I trials. Both compounds target the novel NS5a protein but have completely different chemical structures and bind to the target at different sites.

Once again A-689 originates from Arrow's focused chemical library and was optimised inhouse. According to the company, the compound has shown highly potent activity in the replicon assay and has an excellent therapeutic index and good pharmacokinetic properties. Phase I trials on A-689 are planned for the second half of 2007.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance